Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Inclusion Criteria: * Written informed consent must be given according to ICH/GCP and national/local regulations. * Histological or cytological proof of metastatic CRC. * Disease progression or relapse after at least one line of treatment for advanced CRC with a fluoropyrimidine containing chemotherapy as single agent or in combination (combinations with oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab are allowed). * Written documentation of positivity for MSI-like gene signature as determined by Agendia test. * Unresectable disease, with at least one measurable lesion according to RECIST 1.1. * Age ≥ 18 years. * WHO performance status of 0-1. * Ability and capacity to comply with study and follow-up procedures. * Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 28 calendar days prior to the first study treatment: * ANC \> 1.5 x 109/L (without granulocyte colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1) * WBC counts \> 2500/μL * Platelet count \> 100,000/ μL (without transfusion within 2 weeks prior to Cycle 1, Day 1) * Hemoglobin \> 9.0 g/dL * AST, ALT, and alkaline phosphatase \< 2.5 x ULN, with the following exceptions: * Patients with documented liver metastases: AST and ALT \< 5 x ULN * Patients with documented liver or bone metastases: alkaline phosphatase \< 5 x ULN Bilirubin \<1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level \< 3 x ULN…